Cayuga is Awarded 2026 MTEC Prototype of the Year Award
First Subject Dosed in Phase 1 Clinical Trial for CAY001 for Life-Threatening Hemorrhage
Cayuga Closes $8M Seed Funding
Full Data on Cayuga’s Novel Synthetic Compound in Stopping Life-Threatening Hemorrhage Shows Promise
Cayuga’s CAY001 Significantly Increases Survival and Improves Bleeding Outcomes in Platelet Inhibitor-Related Bleeding
Cayuga’s poly-P-SNP Complex Demonstrates >90% Shorter Bleeding Time and Nearly 60% Less Blood Loss After Severe Injury
NuFund Venture Group Celebrates Cayuga Biotech’s Breakthroughs in Hemorrhage Therapy
Cayuga Awarded Best Oral Presentation – Plasma, Hemostasis and Transfusion Medicine at the 19th International Symposium on Blood Substitutes
Cayuga Biotech to Present Data at the 19th ISBS Meeting
Cayuga Biotech to Present Data at the 66th ASH Annual Meeting
Cayuga Biotech Announces That PolyP-SNP Complex Data Demonstrate Potential to Address Top Causes of Death from Hemorrhage After Battlefield Injury
Cayuga Biotech Announces that PolyP-SNP Complex Data Demonstrate 12x Faster Coagulation in Life-Threatening Hemorrhage
Cayuga Biotech Participates in NuFund Panel on Women Founders and Funders
Cayuga to Present Data as a Poster Presentation at the 2024 Military Health System Research Symposium (MHSRS) for the session, “Technologies for the Treatment of Battlefield Hemorrhage and Management of Vascular Dysfunction”
Cayuga Named Finalist Army xTechSearch Prize Competition
Cayuga Biotech Appoints Andrea Ashford-Hicks as Chief Executive Officer
Cayuga Participates in IndieBio Launch Pad for Early-Stage Biotech
Cayuga Wins 2020 University of California Startup Pitch Showcase
Damien Kudela Presents “Smart Drugs to Stop Bleeding” at UCSB Grad Slam
